The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Does omidubicel lead to better outcomes than conventional cord blood transplantation?

During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Mitchell E. Horwitz, Duke University School of Medicine, Durham, US. We asked, Does omidubicel lead to better outcomes than conventional cord blood transplantation?

Does omidubicel lead to better outcomes than conventional cord blood transplantation?

Omidubicel is an ex vivo expanded umbilical cord blood graft, designed to reduce time to neutrophil engraftment. Horwitz describes a phase III study comparing the efficacy of omidubicel transplant with conventional umbilical cord blood transplantation.

 

Share:
More about...